CD38 and plasma cell myeloma: Since EZH2 inhibition is already approved for the treatment of B cell lymphoma [16], we believe our study may provide new therapeutic avenues to investigate the efficacy of EZH2 inhibition as a strategy to re-sensitize myeloma cells to anti-CD38 MoAbs and overcome resistance.